Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study
In this long-term, real-world, national cohort, switching to DTG+3TC was associated with low rates of VF and antiretroviral therapy resistance, indicating that eligible individuals can be switched to DTG+3TC without increased risk of VF.
Authors
- Johanna Repits
- Erik Sörstedt (ORCID: https://orcid.org/0000-0001-6966-7485)
- Johanna Brännström (ORCID: https://orcid.org/0000-0001-7684-8591)
- George M. Nduva (ORCID: https://orcid.org/0000-0003-3009-4936)
- Fredrik Månsson
- Christina Carlander (ORCID: https://orcid.org/0000-0001-9962-5964)
- Åsa Mellgren (ORCID: https://orcid.org/0000-0002-1202-3504)
- E. Fernvik
- Melanie Schroeder
- Adam Stubbs
Institutions
- Karolinska University Hospital (SE)
- Malmö University (SE)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
- Region Västra Götaland (SE)
- ViiV Healthcare (United Kingdom) (GB)
- GlaxoSmithKline (Sweden) (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Journal of the International AIDS Society
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1002/jia2.70054
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00